Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system
Anna B. Pierce A C F , Carol El-Hayek B , Damien McCarthy B , Jude Armishaw A , Kerrie Watson A C , Anna Wilkinson B E , Brian Price A C , Edwina J. Wright A C D , Jennifer F. Hoy A C and Mark A. Stoové B EA Victorian NPEP Service, Department of Infectious Diseases, The Alfred Hospital, Level 2 Burnet Building, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
B Centre for Population Health, The Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
C Department of Infectious Diseases, Monash University, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
D Centre for Biomedical Research, The Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
E School of Public Health and Preventive Medicine, Monash University, Commercial Road, Melbourne, Vic. 3004, Australia.
F Corresponding author. Email: a.pierce@alfred.org.au
Sexual Health 14(2) 179-187 https://doi.org/10.1071/SH16132
Submitted: 30 June 2016 Accepted: 16 September 2016 Published: 5 December 2016
Abstract
Background: International non-occupational post-exposure prophylaxis (NPEP) guidelines recommend routine use of three drug NPEP regimens, despite absence of evidence for greater prevention efficacy compared with two drug regimens. This study examines the potential for excess HIV seroconversions among high-risk men who have sex with men (MSM) reporting receptive anal intercourse with a source of unknown HIV serostatus (RAIU) following a two-drug versus a three-drug NPEP regimen. Methods: Data for MSM in the Victorian NPEP service database between 10 August 2005 and 31 December 2012 were linked with all Victorian HIV notifications up to 31 December 2013. The primary outcome was NPEP failure following NPEP presentation among MSM reporting RAIU, stratified by the number of drugs prescribed. Results: Among 1482 MSM reporting 2002 episodes of RAIU and prescribed two- or three-drug NPEP, 70 seroconverted to HIV, but only 19 were considered possible NPEP failures. HIV diagnosis incidence among men reporting RAIU was 1.2/100 person years (PY) (95%CI = 1.0–1.6); 1.1/100 PY (95%CI = 0.8–1.4) among MSM prescribed two drugs and 2.2/100 PY (95%CI = 1.4–3.7) among MSM prescribed three drugs (P < 0.01). Of the 19 possible NPEP failures, 13 (0.7%) were prescribed two drugs and six (2.7%) three drugs (P < 0.001). Conclusions: This study suggests that two-drug NPEP regimens do not result in excess seroconversions compared with three-drug regimens when used following RAIU. Clinical services should carefully consider their use of three drug NPEP and whether resources might be better invested in other prevention strategies, particularly pre-exposure prophylaxis (PrEP).
Additional keywords: NPEP, HIV prevention, HIV incidence.
References
[1] Jain S, Mayer KH. Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS 2014; 28 1545–54.| Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXhslWiur7F&md5=6eb72df0bb05cad0514933412007a1a2CAS |
[2] New York State Department of Health AIDS Institute. Update: HIV prophylaxis following non-occupational exposure, October 2014. Available online at: http://www.hivguidelines.org/wp-content/uploads/ 2016/03/nPEP_for-PDF_11-29-14.pdf [verified 8 March 2015].
[3] Benn P, Fisher M, Kulasegaram R. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2011; 22 695–708.
| UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC387nslarsw%3D%3D&md5=2c23d4637a33de797421436de8688270CAS |
[4] Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al Updated US Public Health service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34 875–92.
| Updated US Public Health service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.Crossref | GoogleScholarGoogle Scholar |
[5] European AIDS Clinical Society Guidelines version 7.02 June 2014. Available online at: http://www.eacsociety.org/files/guidelines_english_71_141204.pdf [verified 8 March 2015].
[6] World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. World Health Organization. December 2014 Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available online at: http://apps.who.int/iris/bitstream/10665/145719/1/9789241508193_eng.pdf?ua=1&ua=1 [verified 8 March 2015].
[7] Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 853–60.
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.Crossref | GoogleScholarGoogle Scholar |
[8] Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, et al Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366 2368–79.
| Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XpvV2msr8%3D&md5=fe2886ec58b72d255521387e0cb0c690CAS |
[9] AIDSinfo. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 28 March 2014. Available online at: http://aidsinfo.nih.gov/guidelines. [verified 14 August 2013].
[10] The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report 2014. Sydney: The Kirby Institute, the University of New South Wales; 2014.
[11] Pedrana AE, Hellard ME, Wilson K, Guy R, Stoove M. High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia. J Acquir Immune Defic Syndr 2012; 59 94–9.
| High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia.Crossref | GoogleScholarGoogle Scholar |
[12] Australian Government Department of Health and Ageing. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV, 2013. Available online at: http://www.ashm.org.au/pep-guidelines/NPEPPEPGuidelinesDec2013.pdf [verified 8 March 2015].
[13] Armishaw J, Hoy JF, Watson KM, Wright EJ, Price BG, Pierce AB. Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up. Int J STD AIDS 2011; 22 714–8.
| Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38%2FnvVehtA%3D%3D&md5=139bfffc0b589d9c5b2fa97c39d54640CAS |
[14] Horyniak D, Stoove M, Yohannes K, Breschkin A, Carter T, Hatch B, et al The impact of immigration on the burden of HIV infection in Victoria, Australia. Sex Health 2009; 6 123–8.
| The impact of immigration on the burden of HIV infection in Victoria, Australia.Crossref | GoogleScholarGoogle Scholar |
[15] Goller JL, Guy RJ, Gold J, Lim MS, El-Hayek C, Stoové MA, et al Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings. Sex Health 2010; 7 425–33.
| Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings.Crossref | GoogleScholarGoogle Scholar |
[16] Cleves M. StataCorp. Analysis of multiple failure-time survival data. November 1999; updated July 2009. Available online at: http://www.stata.com/support/faqs/statistics/multiple-failure-time-data/ [verified 8 March 2015].
[17] Jain S, Oldenburg CE, Mimiaga MJ, Mayer KH. Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston Community Health Center: 1997–2013. AIDS Patient Care STDS 2015; 29 20–5.
| Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston Community Health Center: 1997–2013.Crossref | GoogleScholarGoogle Scholar |
[18] Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXit1ansg%3D%3D&md5=6e22600cda8924441c0d2faa55711ff6CAS |
[19] Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367 399–410.
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlSltrbK&md5=3cb82387c09c4694dae4fa80e1fa8ad3CAS |
[20] Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14 820–9.
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.Crossref | GoogleScholarGoogle Scholar |
[21] Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373 2237–46.
| On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC28XntFSnsLc%3D&md5=af2ecb0d01037a9c93f407579f51b170CAS |
[22] Thigpen MC, Kebaabetswe PM, Paxton LA, Smih DK, Rose CE, Segoldi TM, et al Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367 423–34.
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlSltrbE&md5=06ad452c0b2648054b2e24effdfd7b92CAS |
[23] Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59 354–9.
| Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xjsleht7g%3D&md5=608409dfbe99ac7dd6e611835090ebedCAS |
[24] Wilkinson AL, El-Hayek C, Spelman T, Fairley C, Leslie D, McBryde E, et al ‘Seek, test, treat’ lessons from Australia: a study of HIV testing patterns from a cohort of men who have sex with men. J Acquir Immune Defic Syndr 2015; 69 460–5.
| ‘Seek, test, treat’ lessons from Australia: a study of HIV testing patterns from a cohort of men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[25] Heuker J, Sonder GJ, Stolte I, Geskus R, van den Hoek A. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000–2009: indications for ongoing sexual risk behaviour. AIDS 2012; 26 505–12.
| High HIV incidence among MSM prescribed postexposure prophylaxis, 2000–2009: indications for ongoing sexual risk behaviour.Crossref | GoogleScholarGoogle Scholar |
